Abstract

This article reviews several important observations in the field of protein kinase drug discovery, exemplified mainly by targeting c-Abl for the treatment of CML. Structure-based strategy and insight are provided for the optimization of the selectivity and resistant mutation profiles of protein kinase inhibitors.

Keywords: Protein kinase, protein kinase inhibitor, selectivity, imatinib, CML, drug-resistant mutation, systematic structural analysis